Stock Analysis
Bristol-Myers Squibb Company (BMY) Stock Analysis
Bristol-Myers Squibb Company (BMY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Bristol-Myers Squibb Company (BMY) currently has an AIQ Score of 59/100, indicating a neutral setup. Quality is the strongest factor at 71/100. Risk is the weakest current factor at 41/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BMY at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $61.12 |
| AIQ Score | 59/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Buy |
| Market Cap | $136.7B |
| P/E Ratio (TTM) | 14.74 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $1.62 |
| Revenue (quarter ended 2026-06-30) | $12.97B |
| Dividend Yield (TTM) | 3.75% |
| Beta | 0.23 |
| Volume | 9.02M |
| 52-week range | $42.52-$68.64 |
| RSI 14 | 48.91 |
| 50-Day SMA | $63.28 |
| 200-Day SMA | $59.75 |
| Analyst Price Target | $65.54 |
| Next Earnings | Oct 29, 2026 |
BMYBristol-Myers Squibb Company
Healthcare / Drug Manufacturers - General
Low Priority
Above Peers
Latest quote
- Momentum48
- Value65
- Quality71
- Risk resilience41
- Sentiment50
BMY Stock Analysis Summary
Bristol-Myers Squibb Company (BMY) currently has an AIQ Score of 59/100, indicating a neutral setup. Quality is the strongest factor at 71/100. Risk resilience is the weakest current factor at 41/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, BMY has AIQ Score of 59/100 with Quality base of 71/100 and fading Risk resilience at 41/100. Wait for component alignment before adding exposure.
Quality (71/100) leads while Risk resilience (41/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.91% stock move · BMY classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BMY Bullish or Bearish Right Now?
BMY currently has a neutral overall setup. Quality is the strongest factor at 71/100, while Risk Resilience is weakest at 41/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 71/100.
- - Analyst target implies +7.23% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (23 vs 13).
- - Risk Resilience is weak at 41/100.
Current Consensus
BMY's Technical Analysis Consensus is currently Buy, with 23 buy, 9 neutral, and 13 sell votes. BMY's 14-day RSI is 48.91, which places the stock in a neutral momentum range. BMY's beta is 0.23, indicating lower market sensitivity than the broad market.
What Changed in BMY?
The largest recent change in BMY is Momentum moving up by 14.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the BMY Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BMY Decision Framework
Public evidence layers, setup checks, and risk context for Bristol-Myers Squibb Company.
Bristol-Myers Squibb Company (BMY) Stock Analysis
Bristol-Myers Squibb Company has an AIQ Score of 59/100 in a Neutral regime. Quality is strongest at 71/100. Beta is 0.23, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BMY is in a Neutral AIQ regime with score 59/100. |
| Signal Conflict | The primary conflict is that quality leads at 71/100 while risk lags at 41/100. |
| Factor Evidence | Momentum 48/100 · Value 65/100 · Quality 71/100 · Risk 41/100 · Sentiment 50/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 71/100.
Momentum is 48/100 and RSI (14) is 48.9.
BMY is in a Neutral regime at 59/100.
Risk factor is 41/100 with beta 0.23 and annual volatility 28.27%.
Current conflict: quality leads at 71/100 while risk lags at 41/100.
BMY Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BMY Fundamentals
BMY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BMY Technical Analysis
BMY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BMY Stock Catalysts
Track BMY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BMY Dividend Analysis
BMY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BMY Financial Data
BMY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BMY Risk Analysis
BMY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BMY Stock News
BMY stock news, market tone, recent headlines, and catalyst context.
BMY vs Large Cap Pharma Peers
Current peer cohort: BMY · BNTX · GILD · GSK · HLN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BMY Current stock | 59/100 | 65/100 | 48/100 | 41/100 | 1.2 | 28.27% | Current |
| BNTX BioNTech | 46/100 | 35/100 | 32/100 | 64/100 | -0.21 | 46.82% | BMY vs BNTX |
| GILD Gilead Sciences | 45/100 | 37/100 | 71/100 | 45/100 | 0.81 | 26.86% | BMY vs GILD |
| GSK GSK | 67/100 | 67/100 | 72/100 | 49/100 | 0.46 | 26.66% | BMY vs GSK |
| HLN Haleon | 62/100 | 56/100 | 79/100 | 48/100 | 0.22 | 23.24% | BMY vs HLN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BMY
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BMY
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BMY Stock FAQ
What is BMY stock price today?
Bristol-Myers Squibb Company's current stock price is $61.12. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BMY bullish or bearish right now?
BMY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BMY's market cap?
BMY's market cap is $136.7B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BMY's current P/E ratio?
BMY's current P/E ratio is 14.74 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BMY's RSI?
BMY's 14-day RSI is 48.91 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BMY above its 50-day and 200-day moving averages?
BMY is -3.41% from its 50-day SMA and 2.30% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BMY's next earnings date?
BMY's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BMY pay a dividend?
BMY's dividend yield is 3.75% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.